Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.

Blood
M L DisisK Schiffman

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells and have shown promise to function as "natural" vaccine adjuvants. Currently, most cancer vaccine trials using DCs generate autologous DCs ex vivo for each patient. Systemic treatment with Flt3 ligand (FL) results in a marked increase of DCs in tissues such as spleen and lymph nodes in mice and in the peripheral blood and skin of humans. In light of these observations, we questioned whether FL could be used systemically as a vaccine adjuvant to stimulate DC mobilization in vivo, circumventing the need to generate DCs ex vivo. Ten patients with HER-2/neu-overexpressing cancer were enrolled in a phase 1 study to receive a HER-2/neu peptide-based vaccine targeting the intracellular domain of the HER-2/neu protein. All patients received 20 microg/kg FL per day subcutaneously for 14 days. Five patients received the HER-2/neu peptide-based vaccine alone on day 7 of the 14-day cycle, and 5 patients received the vaccine admixed with 150 microg granulocyte macrophage-colony-stimulating factor (GM-CSF) on day 7 of the FL cycle. T-cell proliferative responses to HER-2/neu peptides and intracellular domain protein suggest that vaccine regimens including FL as an adjuvant were not ef...Continue Reading

References

Jan 1, 1993·Annual Review of Immunology·E E SercarzK Moudgil
Jan 7, 1998·Critical Reviews in Immunology·M L Disis, M A Cheever
Aug 8, 1998·Trends in Cell Biology·I MellmanR M Steinman
Dec 8, 1998·The Journal of Experimental Medicine·B PulendranC R Maliszewski
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·H DrakesmithB Chain
Dec 14, 1999·The Journal of Investigative Dermatology·C EscheM R Shurin
Mar 29, 2000·The British Journal of Dermatology·I KimberC E Griffiths
Apr 26, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S AielloG Remuzzi
Sep 30, 2000·Clinical and Experimental Dermatology·M CumberbatchI Kimber
Feb 24, 2001·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N S KatsenelsonM R Shurin
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·L FongE G Engleman

❮ Previous
Next ❯

Citations

Jun 11, 2005·Cancer Immunology, Immunotherapy : CII·Constantin N BaxevanisMichael Papamichail
Feb 15, 2008·Cancer Immunology, Immunotherapy : CII·Wei-Zen WeiYi-chi M Kong
Mar 17, 2004·Current Opinion in Immunology·Scott AntoniaJeffrey S Weber
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Jul 20, 2010·Immunotherapy·Constantin N BaxevanisMichael Papamichail
Mar 10, 2004·Journal of Women's Health·Jodi Godfrey
Feb 19, 2011·Current Oncology·A FlorescuM Clemons
Jan 15, 2013·Drug Delivery and Translational Research·Mehfuz ZamanIstvan Toth
May 12, 2011·International Reviews of Immunology·Cheryl Lai-Lai ChiangGeorge Coukos
Jun 5, 2004·Expert Review of Vaccines·Leona A Holmberg, Brenda Sandmaier
Sep 23, 2008·Expert Opinion on Pharmacotherapy·Peng H Tan, Amrit S Lota
Mar 5, 2004·Expert Opinion on Biological Therapy·Joeli A BrinkmanW Martin Kast
Oct 21, 2004·Cancer Investigation·Prahlad Parajuli, Andrew E Sloan
Mar 5, 2016·Current Treatment Options in Oncology·Nicola HardwickMihaela Cristea
Jul 17, 2007·Vaccine·Valéry Renard, Dana R Leach
May 12, 2005·Journal of Cellular Physiology·Serenella M PupaAndrea Anichini
Jul 20, 2007·International Journal of Cancer. Journal International Du Cancer·Ioannis F VoutsasConstantin N Baxevanis
Dec 9, 2004·Immunology Letters·Douglas G McNeel, Miroslav Malkovsky
Jul 6, 2004·Clinical Biochemistry·Srinivasan Madhusudan, Trivadi S Ganesan
Dec 25, 2012·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Aug 25, 2011·Cytokine & Growth Factor Reviews·William K Decker, Amar Safdar
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberMary L Disis
May 26, 2017·International Journal of Molecular Sciences·Panagiotis TsapogasAntonius Rolink
Sep 18, 2014·The Cochrane Database of Systematic Reviews·Ninke LeffersHans W Nijman
Sep 11, 2018·The Cochrane Database of Systematic Reviews·Sterre T PaijensHans W Nijman
Sep 17, 2003·Nature Reviews. Immunology·Olivera J Finn
May 12, 2011·International Reviews of Immunology·Suzanne R Thibodeaux, Tyler J Curiel
Jun 21, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Angelos D GritzapisConstantin N Baxevanis
May 26, 2017·Biomedicines·Silvia Martin LluesmaLana E Kandalaft
Aug 6, 2011·Cancer Research·Sebastian KreiterUgur Sahin
Nov 11, 2020·Vaccines·Stephanie ChowOliver Dorigo
Apr 4, 2021·Cancers·Francisco J Cueto, David Sancho
Dec 1, 2021·Breast Cancer Research and Treatment·Mary L Disis, Denise L Cecil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.